Processing

Please wait...

Settings

Settings

Goto Application

1. WO2018067575 - COMBINATION DRUG THERAPY REDUCES PARP-1 RELATED DNA REPAIR AND INCREASES THE EFFICACY OF GENOTOXIC AGENTS

Publication Number WO/2018/067575
Publication Date 12.04.2018
International Application No. PCT/US2017/054950
International Filing Date 03.10.2017
IPC
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61K 31/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
CPC
A61K 2300/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
2300Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K 31/137
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
135having aromatic rings ; , e.g. ketamine, nortriptyline
137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine ; or methadone
A61K 31/337
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
337having four-membered rings, e.g. taxol
A61K 31/4184
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4184condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
445Non condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Applicants
  • INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION [US]/[US]
Inventors
  • ZHANG, Jian-Ting
  • LIU, Jian-Yuan
Agents
  • CHO, Taewoo
Priority Data
62/403,42303.10.2016US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION DRUG THERAPY REDUCES PARP-1 RELATED DNA REPAIR AND INCREASES THE EFFICACY OF GENOTOXIC AGENTS
(FR) THÉRAPIE À BASE DE MÉDICAMENTS EN ASSOCIATION RÉDUISANT LA RÉPARATION DE L'ADN ASSOCIÉE À LA PARP-1 ET AUGMENTANT L'EFFICACITÉ DES AGENTS GÉNOTOXIQUES
Abstract
(EN) Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reduction of resistence to the treatment, prevention, and/or diagnosis of diseases characterized by the formation of cancers. Embodiments include methods of treating cancer, comprising the steps of: providing a patient diagnosed with cancer with a therapeutic regime that includes at least one therapeutically effective dose of at least one agent that reduces the activity of at least one DNA damage/repair pathway. Other embodiments include methods of treating cancer, comprising the steps of: treating a patient diagnosed with cancer with a combination of therapeutic agents that includes at least one therapeutically effective anti-cancer agent and at least one compound that reduces the activity of at least one DNA damage/repair pathway. Yet other embodiments include methods of reducing resistance to a genotoxic therapeutic, comprising the steps of: treating a patient at least one therapeutically effective dose of at least one agent that reduces at least one DNA damage/repair pathway.
(FR) Divers aspects et modes de réalisation de la présente invention concernent de manière générale la modélisation, le traitement, la réduction de la résistance au traitement, la prévention et/ou le diagnostic de maladies caractérisées par la formation de cancers. Des modes de réalisation incluent des procédés de traitement du cancer, comprenant les étapes suivantes : administration, à un patient sur lequel a été diagnostiqué un cancer, d'un régime thérapeutique qui comprend au moins une dose thérapeutiquement efficace d'au moins un agent qui réduit l'activité d'au moins une voie d'endommagement/de réparation de l'ADN. D'autres modes de réalisation incluent des procédés de traitement du cancer, comprenant les étapes suivantes : traitement d'un patient sur lequel a été diagnostiqué un cancer avec une combinaison d'agents thérapeutiques qui comprend au moins un agent anticancéreux thérapeutiquement efficace et au moins un composé qui réduit l'activité d'au moins une voie d'endommagement/de réparation de l'ADN. Encore d'autres modes de réalisation incluent des procédés de réduction de la résistance à un agent thérapeutique génotoxique, comprenant les étapes suivantes : traitement d'un patient avec au moins une dose thérapeutiquement efficace d'au moins un agent qui réduit au moins une voie d'endommagement/de réparation de l'ADN.
Related patent documents
Latest bibliographic data on file with the International Bureau